The Munich-based biotech company adivo, which focuses on the development of species-specific therapeutic antibodies for companion animals, has received seed financing from three investors.
The company aims to meet the high demand for novel drugs to treat cancer and chronic inflammatory diseases in dogs, with the potential to expand these activities to other animal species in the future.
adivo seeks cooperation with pharmaceutical partners
"We are very pleased to have gained three strong and reliable partners who share our vision of driving innovation in veterinary medicine. High-Tech Gründerfonds (HTGF), Occident Group AG, and MorphoSys AG are jointly laying the foundation for the company's future success as strategic investors. We will use the investments to advance our therapeutic antibody programs and continuously improve the adivo technology. At the same time, we are seeking collaborations with pharmaceutical partners to leverage our technology platform for numerous additional projects."
so Dr. Kathrin Ladetzki-Baehs, Managing Director of adivo GmbH.
“Highly motivated employees with powerful technology”
"We are pleased to be invested in a company that combines highly motivated employees with powerful technology. adivo will soon offer new therapies for the veterinary market that can help provide even better medical care for animals."
said Cédric Barra, Investment Manager Lifesciences at Occident Group.
The Munich-based start-up was founded in 2018 and is a spin-out of MorphoSysIt is located in Innovation and start-up center for biotechnology in Martinsried.
